Table 1. Characteristics of the studies included in the meta-analysis.
| Study | Cases/Male(n) | Location/Ethnicity | Age(years) | Immunosuppressive protocol a | Initial dose of tacrolimus(mg/kg/day) | Desired trough concentration(ng/ml) | Hardy-Weinberg equilibrium | Allele frequencies of CYP3A4 (%) | |
|---|---|---|---|---|---|---|---|---|---|
| *1 | *1B | ||||||||
| Kurzawski 2014 [ 19 ] | 241/134 | Poland/Caucasian | 45.8+/-12.4 | Tac+MMF+steroids | 0.1 | 1st month:10–15;Subsequent:8–10 | Yes | 96.9 | 3.1 |
| Tavira 2013 [ 20 ] | 206/126 | Spain/Caucasian | 48.6+/-13.5 | Tac+MMF+prednisone | 0.2 | 0–3 months:10–15;Subsequent:5–15 | Yes | 97.1 | 2.9 |
| Gervasini 2012 [ 21 ] | 103/62 | Spain/Caucasian | 48.7+/-16.9 | Tac+MMF+steroids | 0.2 | 0–3 months:10–15;Subsequent:5–10 b | Yes | 97.6 | 2.4 |
| Tavira 2011 [ 22 ] | 400/242 | Spain/Caucasian | 48.02+/-13.29 | Tac+MMF+prednisone | 0.2 | 0–3 months:10–15;Subsequent:5–10 | Yes | 96.9 | 3.1 |
| Singh 2009 [ 23 ] | 73/NA | India/North Indian | NA | Tac+MMF/Aza+prednisolone | 0.16 | 1st month: 10–12;3rd month:8–10 | No | 97.3 | 2.7 |
| Kuypers 2007 [ 24 ] | 95/57 | Belgium/Caucasian | 51.3+/-14.1 | Tac+MMF+methylprednisolone | 0.2 | 8–15 | Yes | 96.3 | 3.7 |
| Hesselink 2003 [ 25 ] | 64/34 | Netherlands/Asian,Black & White | NA | NA | 0.2–0.3 | NA | No | 89.8 | 10.2 |
NA: not available.
aTac: tacrolimus; MMF: mycophenolate mofetil; Aza: Azathioprine.
bBetween October 2001 and February 2003, 7–15 ng/ml between June 2000 and September 2001.